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Aims:The purpose of this study was to examine the long-term effects of baclofen in a large
cohort of alcohol-dependent patients compliant to baclofen treatment. Methods: A hun-
dred patients with alcohol dependence, resistant to usual treatments, were treated with
escalating doses of baclofen (no superior limit). Alcohol consumption (in grams) and craving
for alcohol were assessed before treatment and at 3, 6, 12, and 24 months. Assessments
were simply based on patients’ statements. The outcome measure was the consump-
tion of alcohol, rated according to the World Health Organization criteria for risk of chronic
harm. Results:While all patients were rated “at high risk” at baseline, approximately half
of them were rated “at low risk” at 3, 6, 12, and 24 months. The sum of patients who
were at “low risk” and at “moderate risk” (improved patients) was 84% at 3 months,
70% at 6 months, 63% at 1 year, and 62% at 2 years. The constancy of improvement over
the 2-years was remarkable.The average maximal dose of baclofen taken was 147 mg/day.
Ninety-two percentage of patients reported that they experienced the craving-suppressing
effect of baclofen. Significant relationships were found between the amount in grams of
alcohol taken before treatment and the maximal dose of baclofen required, and between
the existence of a mental disorder and a lesser effect of baclofen. Conclusion: Baclofen
produces an effortless decrease or suppression of alcohol craving when it is prescribed
with no superior limit of dose. Potential limitations in the effectiveness of baclofen include
the coexistence of a mental disorder, the concomitant use of other psychotropic drugs, a
lack of real motivation in patients to stop drinking, and the impossibility to reach the optimal
dose of baclofen because of unbearable side-effects (sometimes possibly related to too
sharp a protocol of dose escalation).
Keywords: alcoholism, craving, mental disorder, psychotropic drug
INTRODUCTION
Converging evidence suggest that the gamma-aminobutyric acid-
B receptor agonist baclofen is a promising agent for the treatment
of alcoholism. While a low dose (30 mg/day) of baclofen signif-
icantly decreases alcohol intake (Addolorato et al., 2000, 2002),
high-dose baclofen may promote sustained complete abstinence,
as shown in several case reports (Ameisen, 2005; Agabio et al., 2007;
Bucknam, 2007; Pastor et al., 2012) and in series of patients (Dore
et al., 2011; Rigal et al., 2012). However, a number of patients
do not respond optimally to high-dose baclofen. In the Dore et
al. and Rigal et al. studies, an insufficient efficacy of baclofen
was reported in 40–50% of the cases. Rigal et al. showed that
the existence of a mental illness and the concomitant use of psy-
chotropic drugs are significantly associated with a reduced efficacy
of baclofen. A reduced efficacy of baclofen may also theoretically
be related to a number of other factors (i.e., genes, environ-
ment, motivation, enduring habits, severity of alcohol dependence,
severity of side-effects, treatment observance), which remain to
be investigated. In addition, clinicians use different protocols of
treatment, and the optimal protocol of treatment with baclofen
in alcoholism is not well established. Studies investigating the
long-term effects of baclofen in large cohorts of patients should
help to characterize some of the factors affecting the efficacy of
baclofen.
The present study is a long-term observational study aiming
to record precisely the successes and failures of baclofen treat-
ment in alcohol-dependent patients resistant to usual treatments.
A hundred consecutively treated patients, all observant to baclofen
treatment, were included and followed over 2 years. The effective-
ness of baclofen, its undesirable side-effects, and the number of
treatment discontinuations were recorded. Preliminary reports on
the present study have been published by Ameisen and de Beau-
repaire (2010) (60 patients over 6 months), and by Rigal et al.
(2012) (a 1-year retrospective study including 67 of the patients
of the present study).
METHODS
Prescriptions started in November 2008, following the publication
in France of Olivier Ameisen’s book reporting his experience with
baclofen (Ameisen, 2008). One hundred and thirty-two alcohol-
dependent patients (DSM-IV criteria) were consecutively seen
between November 2008 and August 2009. Among them, 32 were
excluded because they were lost before the third month of follow-
up (some of them provided no feedback after the first visit, others
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stopped taking their medication rapidly, generally arguing they
could not bear the adverse effects of baclofen, and some acknowl-
edged that they were not motivated to stop drinking). These
patients were not included in the follow-up because the purpose
of the study is to evaluate precisely the effects of baclofen, and
treatment-observant patients are needed to achieve this objective
(this is not a study based on the intention-to-treat principle). The
follow-up of the 100 remaining patients was used for analysis. The
effects of baclofen during the 3 first months were not included in
the analyses according to the concept of “grace period.” A “grace
period” is an early period in a trial where outcome is not con-
sidered in the analysis because the effect of the treatment during
this period does not represent the full potential of the drug (FDA,
2006; Falk et al., 2010).
Craving for alcohol and alcohol consumption (in grams)
were assessed before treatment and at 3, 6, 12, and 24 months.
Assessments were based on patients’ statements (no scales used).
Alcohol craving was assessed by two means: (1) Using a visual
analogic scale (VAS, score 0–10), (2) The own clinical impres-
sion of the author based on the patient’s statements. Given that
the VAS appeared to fluctuate according to the patient’s state of
mind, optimistic or pessimistic, and was difficult to analyze in
these conditions, the author chose to use his clinical assessment,
which provided a clear binary appraisal: yes or no (a change
or no change in the patient’s craving). The outcome measure
was the consumption of alcohol according to the World Health
Organization (WHO) criteria for chronic harm (World Health
Organization, 2000): patients were rated “at low risk” (i.e., nor-
mal: below 40 g/day for men and below 20 g/day for women) or “at
medium risk” (between 41 and 60 g/day for men and between 20
and 40 g/day for women) or “at high risk” (superior to 60 g/day for
men and 40 g/day for women). Alcohol consumption recorded at
each time-point was the average daily consumption of alcohol (in
grams) during the 4 weeks before each visit (before enrollment, all
patients were every day heavy drinkers, no one being in remission).
The day of the first visit, patients signed a form establishing
their informed consent and stating that they suffered from a treat-
ment resistant alcoholism and that they wished to try baclofen.
“Treatment resistant alcoholism” means that all patients have been
treated before for their alcoholism, in various ways, including
medications, hospitalizations, rehab centers, Alcoholics Anony-
mous, and psychotherapies, and that these treatments failed. The
form provided all information regarding precautions in the use
of baclofen, its potential adverse effects, the fact that the prescrip-
tion was off-label, the protocol (progressive dose increase) with
the possible necessity of reaching high doses (patients were told
that treatment has to be progressively increased until they feel a
sufficient indifference toward alcohol to stop drinking or com-
pletely control their alcohol intake), and the fact that the personal
physician of the patient would be informed of the prescription.
After signing this form, patients were prescribed baclofen (10 mg
tablets) using the following protocol: 1/2 tablet on day 1 (morn-
ing), 1 tablet on day 2 (1/2 morning, 1/2 noon), 1+ 1/2 tablet on
day 3 (1/2 morning, 1/2 noon, and 1/2 evening), the 1+ 1/2 tablet
being maintained over the four remaining days of the first week.
According to Novartis recommendations of prescription (Vidal,
2008), start with half tablet doses is the appropriate procedure of
treatment. During the second week, the treatment was increased by
three tablets, up to 45 mg/day (1+ 1/2 tablet three times/day), and
to 75 mg during on the third week. Patients were called to a second
visit at the end of the third week or during the fourth week. In case
of ineffectiveness, the treatment was increased by 30 mg/week dur-
ing the following weeks. Patients were asked to submit to monthly
visits. Monthly visits were maintained and patients encouraged to
call if any question or particular event came up. Patients drinking
only at certain hours of the day (often only in the evening) were
advised to increase the dose one hour before the time they usually
drank. Patients were also advised to increase the dose in case of
stress or in response to a moment of craving.
At the end of the first visit, patients were informed that they
were free to drink as usual, given that baclofen is expected to
suppress the motivation to drink. When applicable, patients were
asked to follow their medical treatment and other forms of ther-
apies as before. Drivers were asked not to drive during the first
weeks of treatment because of the risk of somnolence. No ther-
apeutic intervention (psychological, social, or pharmacological)
other than baclofen treatment was initiated or suggested.
All patients provided the name and telephone number of their
attending physician, and the physician was always contacted by
phone (unless the patient had no physician or refused that the
physician be contacted). In many cases, the patient’s physician
took over the prescription after a while. In some other cases,
the treatment was started by a physician before the first visit, so
that the first visit occurred after a period of treatment, in general
because the patient’s physician did not want to increase the doses
(in this case, the starting day of the treatment corresponded to
the moment it was initiated by the physician, and the protocol of
treatment differed from that described above). Four patients had
started treatment by themselves getting baclofen through internet.
As a whole, 24 patients did not use the protocol of dose increase
exactly as described above.
The following items were recorded at the first visit: age, sex,
body weight, and height [the body mass index (BMI) was cal-
culated], drinking history, amount of daily alcohol consumption
(in grams), intensity of craving for alcohol, medical, and psychi-
atric history, present treatments, concomitant addictions, smoking
habits, marital status, and employment. For patients drinking
intermittently, the daily amount of alcohol drunk during heavy
drinking episodes was kept for analysis. When applicable, a psy-
chiatric diagnosis (other than alcoholism) was established based
on present symptoms and the patient’s clinical psychiatric history
(DSM-IV criteria). During the following visits, patients were asked
to report in detail their consumption of alcohol, their craving for
alcohol (similar, decreased, or no longer present), their compli-
ance to treatment (doses of baclofen taken), the side-effects of the
treatment, their smoking habits, and the use of other psychotropic
drugs.
At 3, 6, 12, and 24 months, the effectiveness of the treatment
was rated to fit into one of the three WHO categories: “at low
risk,” “at medium risk” and “at high risk.” In the “at low risk”
category, patients experienced a suppression of craving, and their
complete control over drinking was effortless. In the “at medium
risk” category, patients experienced a clear decrease in craving but,
for various reasons (in general, too strong an attachment to their
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drinking habits associated with an incomplete motivation to cease
drinking), they were not able to control completely their drink-
ing compulsions. In the “at high risk” category, patients either
experienced an insufficient reduction of craving, or, although they
experienced a significant decrease in craving, after a period of
decrease in drinking, relapsed in their addiction. The risk category
was defined according to the control over drinking during the last
4 weeks.
Analysis of relationships between continuous variables was
based on Spearman’s r correlation with asymptotic confidence
intervals based on Fisher’s Z transform. Comparisons of means
were done using Student t -test assuming unequal variance (with
Satterthwaite adjustment for degree of freedom), and chi-squared
tests were used to assess association between categorical variables
in two-way cross-classification table. The association between the
binary outcome (at low risk vs. at medium or high risk) and psy-
chiatric history and actual treatment (benzodiazepines and/or psy-
chotropic drugs) was summarized as odds-ratio computed from
generalized estimating equation models to account for repeated
measurements during follow-up. Three regression models were fit-
ted to available data, using one of the three aforementioned binary
predictors in each model. We consider time treated as a numerical
variable (3, 6, 12, and 18 months), and gender and age as additional
co-factors, assuming an unstructured working correlation matrix.
Statistical analyses were done with R 2.15.1 statistical software (R
Core Team, 2012).
RESULTS
Patients included 70 men and 30 women, with an average age of
47 (men 48, women 45, p= 0.197).
A hundred patients were followed at 3 months, 97 at 6 months,
92 at 12 months,and 87 at 24 months. Among the 13 lost patients at
24 months, 11 had moved providing no feedback, and two had died
(one accidental ingestion of a cleaning product, one false passage –
both unlikely to be related to baclofen treatment). The number of
patients who discontinued baclofen for whatever reason came to
25 at 6 months, 51 at 12 months, and 58 at 24 months.
A summary of patients’ characteristics, according to their
risk status at 3 months, is provided in Table 1. Overall, 51% of
Table 1 | Demographic and biomedical information on participants
3months after treatment.
Not at risk at 3
months (N =50)
At risk at 3
months (N =50)
Overall
(N =100)
Gender (female) 32% (16) 28% (14) 30% (30)
Age (years) 48.7 (10.1) 46.0 (11.3) 47.3 (10.8)
BMI (kg/m2) 25.0 (5.9) 25.0 (4.4) 25.0 (5.2)
Smoking 74% (37) 78% (39) 76% (76)
Active 54% (27) 47% (23) 51% (50*)
Married 58% (29) 47% (23) 53% (52*)
Psychiatric disorder 48% (24) 70% (35) 59% (59)
Psychotrope use 54% (27) 74% (37) 64% (64)
Benzodiazepine 48% (24) 64% (32) 56% (56)
*1 missing observation.
the patients had a job, and 53% were currently living within a
couple (married or not). No significant relationship was found
between these variables and the response to treatment at 3 months
[professional activity, χ2(1)= 0.49, p= 0.482; marital status,
χ2(1)= 1.21, p= 0.270].
Ninety-two patients (92%) reported a decrease in their moti-
vation to drink at one time or another during the follow-up. At
baseline, all patients belonged to the WHO “at high risk” category.
At 3 months, 50% of the responses were classified as “at low risk,”
34% “at medium risk,” and 16% “at high risk”; at 6 months, the
percentages were respectively 52, 18, and 27%, they were 48, 15,
and 29% at 1 year, and 50, 12, and 25 at 2 years (percentages refer
to the 100 patients included; Table 2). Treatment discontinuation
increased over time. At 2 years, 45 patients had stopped their treat-
ment, and this concerned all patients in the “at high risk” group,
10 out of 12 in the “at medium risk” group, and 10 (20%) in the
“at low risk” group.
DOSES
The maximal doses taken by patients ranged from 20 to 330 mg
(Figure 1). The average dose was 147 mg/day. Most of patients
decreased their dose after reaching the maximal dose. There was
no significant correlation between the dose and the response to
treatment. However, there was a significant relationship between
the amount of alcohol (in grams) consumed before treatment
and the maximal dose of baclofen needed by patients [r = 0.315
(0.127;0.482), p= 0.001]. This relationship was significant in both
men and women. Twenty patients did not increase the dose of
baclofen as much as they should have because they could not tol-
erate the side-effects above a certain dose (these patients belonged
to the “at medium risk” and “at high risk” categories). There
were no significant relationships between the maximal doses of
baclofen and the BMI of patients patients [r = 0.069 (−0.130;
0.262), p= 0.498]. The maximal daily dose of baclofen in women
was significantly lower than in men (average 127 mg for women
vs. 158 mg for men, p= 0.025), which may correspond to the fact
that the amount of alcohol consumed before treatment was sig-
nificantly less in women than in men (average daily consumption:
184 g for women vs. 225 g for men, p= 0.010).
CONCOMITANT ILLNESSES AND TREATMENTS
Fifty-nine percent of patients had one or several concomi-
tant psychiatric disorders: anxiety disorder (53%), depression
(34%), bipolar disorder (18%), psychosis (8%), sleep disorder
(42%), other addiction (11%, mostly cannabis), eating disor-
der (5%). The frequency of concomitant psychiatric disorders
was significantly [χ2(1)= 4.54, p= 0.033] higher in females
(n= 23, 76.7%) compared to men (n= 36, 51%). Regarding
actual treatments, no significant differences were found between
men and women (benzodiazepines,p= 0.104; psychotropic drugs,
p= 0.051).
Regression analysis indicated that there was a significant posi-
tive association between the existence of a mental disorder (what-
ever the nature) and an unfavorable outcome [OR= 2.400 (1.515;
3.801), p< 0.001]. Likewise, positive associations were found
between the outcome and use of benzodiazepines [OR= 1.637
(1.053; 2.543), p= 0.028] or psychotropic drugs [OR= 2.064
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Table 2 | Number of patients followed, treatment compliance and categories of patients at each time-point.
Baseline 3months 6months 1 year 2 years
Number of patients 132 100 97 (lost: 3) 92 (lost: 6, deceased: 2) 87 (lost: 11, deceased: 2)
Compliant with treatment – 100 75 (lost: 3, TD: 22) 49 (lost: 6, deceased: 2, TD: 43) 42 (lost: 11 deceased: 2, TD: 45)
At low risk – 50 (TD: 0) 52 (TD: 1) 48 (TD: 7) 50 (TD: 10)
At medium risk – 34 (TD: 0) 18 (TD: 5) 15 (TD: 10) 12 (TD: 10)
At high risk 132 16 (TD: 0) 27 (TD: 16) 29 (TD: 26) 25 (TD: 25)
TD: treatment discontinuation.
FIGURE 1 | Maximal dose taken by patients, with the number of patients for each maximal dose.
(1.308; 3.255), p< 0.002]. In each case, the probability of being
at risk did not evolve significantly with time (Figure 2), and there
were no differences between males and females or according to age
(Table 3).
Thirty-two percent of patients had a somatic illness (mostly
cardiovascular and hepatic). Seventy-six percent of patients were
smokers (Table 1). Among them, nine decreased the number of
cigarettes smoked during baclofen treatment (five stated that the
decrease was related to baclofen treatment), and eight increased
the number of cigarettes smoked.
SIDE-EFFECTS
Eighty-eight percent of patients reported at least one undesirable
side-effect that could possibly be attributable to baclofen. They
were always benign. Side-effects, at one moment or another of
the treatment, independent of their severity or duration, were
the following: substantial fatigue/sleepiness 64%, insomnia 31%,
dizziness 21%, paresthesia 18%, nausea/vomiting 17%, sensory
alterations 16%, sexual changes (decrease or increase of libido)
15%, various forms of pain 20% (including headache 6%), bowel
disorder (diarrhea, constipation) 12%, dysphoria 10%, weight loss
10%, memory loss 9%, hypomania (including one case of clear-
cut mania) 7%, change in eating behavior 7%, weight gain 6%,
sweat/hot flush 6%, tinnitus 6%, mental confusion 5%, cuta-
neous eruption 3%, respiratory difficulties 3%, sugar craving 3%,
other 19% (which included irritability, transient amaurosis, pho-
tosensitization, urine incontinence, cramps, muscular contrac-
tion, muscular spasms, trembling, elocution difficulties, hyper-
sialorrhea, water retention/edema, shouting, electric discharges,
palpitations). No significant relationship was found between
side-effects [globally or individually (when statistically valid)]
and treatment response. No significant relationship was found
between side-effects and the existence of a concomitant mental
disorder.
DISCUSSION
The results of the present study show that treatment with baclofen
at sufficient doses produces a complete and effortless control
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FIGURE 2 | Risk frequency in individuals depending on concomitant illness and treatments.
Table 3 | Parameters estimates for régression models (GEE), assessing for the relation between outcome and (a) psychotrope use, (b)
benzodiazepine, and (c) any psychiatric disorders.
Parameter Estimate SE (robust) Wald z p-Value OR (95% CI)
A
Intercept 0.258 0.560 0.21 0.645 1.294 (0.432; 3.874)
Time −0.013 0.013 0.97 0.325 0.987 (0.961; 1.013)
Use of psychotrope (yes) 0.725 0.233 9.71 0.002 2.064 (1.308; 3.255)
Gender (female) 0.152 0.240 0.40 0.526 1.165 (0.727; 1.864)
Age −0.016 0.001 2.60 0.107 0.984 (0.965; 1.003)
B
Intercept 0.411 0.559 0.54 0.462 1.508 (0.504; 4.513)
Time −0.013 0.013 0.91 0.340 0.987 (0.962; 1.013)
Use of benzodiazepine (yes) 0.493 0.225 4.80 0.028 1.637 (1.053; 2.543)
Gender (female) 0.209 0.238 0.77 0.380 1.233 (0.773; 1.966)
Age −0.015 0.001 2.43 0.119 0.985 (0.966; 1.004)
C
Intercept −0.115 0.581 0.04 0.843 0.891 (0.285; 2.781)
Time −0.014 0.014 1.00 0.318 0.987 (0.961; 1.013)
Psychiatric disorders (yes) 0.875 0.235 13.91 0.000 2.400 (1.515; 3.801)
Gender (female) 0.128 0.238 0.29 0.592 1.136 (0.712; 1.812)
Age −0.009 0.010 0.76 0.383 0.991 (0.971; 1.011)
Reference categories are reported in parenthesis for categorical predictors.
of alcohol dependence in approximately half of the patients
at any given point in time. In addition, 92% of the patients
reported an effortless decrease in their motivation to drink. These
effects may be interpreted according to two parameters: that
of effectiveness (the effect of the treatment on real life behav-
iors) and that of efficacy (the effect on the motivation itself to
drink).
In terms of effectiveness, the highly beneficial effects of baclofen
in the present study were observed at 3, 6 months, 1 year, and
2 years. The number of patients rated “at high risk” increased
between 3 and 6 months, and then stabilized. After 6 months, the
number of patients in each category remained relatively stable.
The low rate of relapse after 6 months in abstinent patients is
remarkable and must be emphasized. The increase in number of
patients rated “at high risk” between 3 and 6 months was due to
the fact that a number of patients who reduced their drinking
after baclofen initiation (rated “at low risk” or “at medium risk”
at 3 months) were unable to maintain a reduced consumption,
likely because of too strong an attachment to drinking habits,
and to an insufficient motivation to quit drinking. Many patients
acknowledged they were ritualized in compulsive drinking and
could not stop drinking even though their appetite for alcohol
was reduced by baclofen. Conversely, many patients needed long
periods of time to go from the categories “at medium risk” or “at
high risk” to the category “at low risk.” These patients clearly expe-
rienced the beneficial effects of baclofen, but had to make strong
efforts to give up their drinking rituals and their attachment to
alcohol. The strength of the willingness to stop drinking may dif-
ferentiate those who relapsed after a period of improvement from
those who progressively improved to reach a complete control over
drinking. Baclofen should be considered a major help for drink-
ing cessation, but other factors (psychological and environmental)
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are likely to play an important role with many patients. Patients
who rapidly succeeded in acquiring complete control over drink-
ing (during the first weeks or months) said that they effortlessly
reached a state of indifference toward drinking (a concept intro-
duced by Ameisen, 2005). This concerned approximately 50% of
the patients. Some patients who had stopped drinking were able
to stop baclofen after a long period of treatment, and did not
relapse (1 patient at 6 months, 7 at 1 year, and 10 at 2 years – how-
ever, several of these patients acknowledged they always kept with
them some tablets of baclofen in case of a sudden craving). Other
patients who had stopped drinking started to experience craving
for alcohol again when they lowered baclofen beneath a certain
dose. No element (BMI, sex, social, family, and professional fea-
tures), with the exception of the amount of alcohol consumed
before treatment, had a predictive value regarding the dose of
baclofen needed, even though the inter-individual variability was
very important. Given that the usual pharmacological treatments
of alcoholism have a limited long-term effectiveness (Johnson,
2008), and although the present study was only observational, it
adds new evidence demonstrating that baclofen is a treatment
of major interest for alcoholism. It should also be noted that, in
addition to the patients abstinent at the different time-points, the
patients who went from the “high risk” category to the “moder-
ate risk” category were also markedly improved, providing a total
of 84% of improvements at 3 months, 70% at 6 months, 63% at
1 year, and 62% at 2 years.
The outcome into the second year of all patients who had
achieved improvement at 1 year shows a remarkable stability. Of
the 48 patients belonging to the “low risk” category at 1 year, 46
were rated in the same category at 2 years. The two patients who
relapsed had episodes of heavy drinking and periods of recov-
ery during the second year, they maintained baclofen treatment,
and were categorized “at medium risk” at 2 years. Three patients
rated “at medium risk” and one “at high risk” at 1 year improved
and were rated “at low risk” at 2 years. These cases illustrate the
great difficulties of some patients to become abstinent despite
the anti-craving effects of baclofen. Among the patients rated
“at low risk” at 2 years, all were not constantly sober during the
year, many (about one third) had moments of short duration
relapses, generally occurring in response of stressful events or sit-
uations, but these short relapses were not sufficient to justify a
change of category. At 2 years, I continue to personally follow 19
of the “at low risk” patients, others are followed by their attend-
ing physician. Besides the fact that 10 patients of the “at low
risk” group had stopped baclofen treatment at 2 years, the major-
ity of 40 remaining patients (31/40) had considerably reduced
baclofen: 167.7 mg/day average maximal dose during the follow-
up, 107.4 mg/day average dose at 2 years (nine patients remained
on their maximal dose).
In terms of efficacy, all patients except eight reported that
baclofen reduced or completely stopped their motivation to drink.
The analysis of the eight cases of patients who reported no
effects of baclofen on craving shows that four of them were
very uncomfortable with baclofen-induced side-effects, and prob-
ably did not reach sufficient doses. For the four remaining
patients (two of them reached doses above 280 mg), the ques-
tion of an insensitivity to baclofen must be raised. Alternative
explanations could be a denial of the effects of baclofen or a
poor compliance with treatment. Further work is necessary to
determine whether certain individuals are really insensitive to
the anti-craving effects of baclofen. Recently, Addolorato et al.
(2011) showed a dose-response effect of baclofen in the treat-
ment of alcohol dependence. There was no dose-response effect
in the present study, but the present study is not in contradic-
tion with the Addolorato et al. study. The goal of the present
study was to increase the doses of baclofen until the achieve-
ment of a complete abstinence, while the goal of the Addolorato et
al. study was to analyze (number of drinks per day) the effect
of two given doses (30 and 60 mg) during a given period of
time. In fact, in the present study, many patients decreased pro-
gressively their drinking, starting to drink less at low doses, but
the doses were nevertheless increased with the aim of reaching
abstinence.
The occurrence of side-effects limited the effectiveness of
baclofen in certain patients. Eleven patients said that they discon-
tinued treatment because they could not tolerate the side-effects,
and 20 patients did not reach an efficacious dose because of the
worsening of side-effects when doses were increased. Even though
a number of patients said they could not tolerate the side-effects of
baclofen, these side-effects were always benign. Side-effects appear
at a certain dose during the dose escalation. Dose escalation may
have been too sharp for certain patients. Slower dose escalation
should be considered.
A fairly high number of patients in the present study presented
with comorbid mental disorders. A significant relationship was
found between the existence of a mental disorder and an unfavor-
able outcome. The relationship was significant at 3 and 6 months,
but not at 1 and 2 years. Of the 50 “at low risk” patients at 2 years,
26 had a comorbid mental disorder, and 24 did not. Therefore,
according to the present study, the existence of a mental disor-
der may compromise improvement at 3 and 6 months, but not
at 2 years. In other words, the coexistence of a mental disorder
may delay the effectiveness of baclofen. Alcohol dependence is
known to be frequently associated with mental disorders, and these
disorders, in particular depression, are known to hamper the effec-
tiveness of treatments (Pettinati, 2004). In the present study, no
significant relationship was found between a less satisfactory out-
come and a particular category of pathology. However, there was
a significant relationship between the use of psychotropic drugs,
particularly benzodiazepines, and a worse outcome. Further work
is needed to determine whether the effect of baclofen could be
dampened by a concomitant treatment with certain psychotropic
drugs, particularly benzodiazepines. It should also be remembered
that people with mental disorders often show a bad compliance
with treatments (Wilder et al., 2010), and some patients in this
category may have been poorly compliant with baclofen in the
present study.
In conclusion, the results of the present study show that
baclofen is very effective in the treatment of alcohol dependence,
and, in particular, extremely efficacious in effortlessly reducing
motivation to drink. High doses of baclofen were often necessary,
but not always, to obtain an optimal effect. The side-effects of
baclofen, the co-occurrence of psychiatric illnesses (possibly the
use of concomitant psychotropic medications), and the absence of
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a strong willingness in some patients to stop drinking, appear to
be the principal limitations to the effectiveness of baclofen. The
possibility that a slowing in dose escalation can reduce side-effects
should be considered.
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